MGC Pharmaceuticals is preparing to move forward with novel, unique and disruptive research in the medical cannabis sector after securing
THE London Stock Exchange’s medical cannabis debutant MGC Pharmaceuticals has released is first quarterly update since listing showing record revenues
LONDON Stock Exchange-listed MGC Pharmaceuticals is to acquire Israeli clinical trial specialist MediCaNL for £3.3m (A$6m) in a share-based transaction. On
CANNABIS shares will be traded for the first time in the 320-year history of the London Stock Exchange today –
PERSISTENCE has paid-off for an Israeli businessman and a UK lawyer after the London Stock Exchange issued its first ever
We won’t spam you
© 2024 Prohibition Holdings Ltd. All Rights Reserved.
